Effect of Sulforaphane on the Vascular Status and Oxidative status of Type 2 Diabetes

Effect of a Sulforaphane-Yielding Encapsulated Product compared with Placebo on Arterial Stiffness and other Biochemical Markers in Type 2 Diabetics aged 18-45 years.

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12612000692831

Acronym

EASY DIAB 2

Enrollment

Registered

2012-06-28

Start date

2012-09-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The prevalence of Type 2 diabetes and its complications is increasing globally. The condition is associated with lifestyle factors which impact biochemically at many levels. Markers of oxidative stress are typically elevated in the diabetic condition but attempts to regulate oxidative stress with antioxidant vitamins have been generally unsuccessful. The plant-derived capsules to be used in this trial yield a phytochemical, sulforaphane which has been shown to activate pathways leading to elevation of the cell's endogenous antioxidant enzymes and other cytoprotective compounds such as glutathione. This trial is aimed at testing the efficacy of such capsules in modifying the disease parameters associated with Type 2 diabetes.

Interventions

ECB capsules each contain 700mg of 100% Myrosinase-active Broccoli Sprout powder. Participants will take 3 capsules night and morning for 26 weeks. All participants will be required to avoid eating cruciferous vegetables because phytochemicals in these foods may activate some of the same pathways as the capsule's active ingredient.

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

18 Years to 45 Years

Healthy volunteers

Inclusion criteria

Medically-diagnosed with Type 2 diabetes without disease complications. Medication schedule must have been stable for at least 6 months and is not expected to change within the next 6 months. Must be able to attend the research clinic on 4 separate occasions over the 6 month-period of the trial. Must be prepared to take 6 plant-based capsules daily and refrain from eating cruciferous vegetables

Exclusion criteria

Evident diabetic complications such as retinopathy, neuropathy and nephropathy. Those whose diabetic condition requires regular insulin. Smokers and those using recreational drugs. Males conusming more than 4 alcoholic drinks and females consuing more than 2 alcoholic drinks daily. Those with BMI > 30 or < 20.

Outcome results